Abstract
Immunotherapy, especially immune checkpoint inhibitors have made a tremendous breakthrough in NSCLC management. Over last decades, ICIs targeting the PD-1, PD-L1 and CTLA-4 have exhibited promising antitumor efficacy and durable response including NSCLC patients with advanced or refractory, metastatic disease. We will provide an overview of mechanism of cancer development and how current available ICIs can be employed to improve patients’ outcome. This review also summarized the discovery process of atezolizumab which led to final FDA approval for its indication. Our major focus is on the significant survival benefit achieved by atezolizumab and taking into consideration of its advantages and disadvantages when we applied it into clinical setting. We hope to help patients and clinicians to better understand the mechanisms, clinical progress and future research direction of NSCLC atezolizumab in decision making.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
